Inflammatory central nervous system disorders
Our clinical group aims to deliver the highest quality translational and clinical research within both investigator- and commercial-led Clinical Trials with a focus on relieving the disease burden of MS on patients and their care givers.
Our current research activities involve:
- Randomized Clinical Trials (RCTs): we are taking part in a number of phase II and phase III clinical trials of novel therapies in pwMS. Furthermore, we are participating in a phase I trial assessing the safety of intratecal neural stem cells (Phase I STEM trial).
- Clinical studies: we are focusing on the identification of predictive factors of response and on the early management of severe adverse events. Moreover, we are conducting studies on different biological factors (Serum Vitamin D, Smoking, Intestinal microbiota, CSF microvescicules, serum neurofilaments and clinical or MRI findings), to find possible correlations with inflammatory and degenerative aspects of MS, their prognostic role in pts at MS onset and in pts during different courses of the disease.
- Genetic studies: we aim at identifying genetic factors involved in susceptibility, disease severity and response to treatments. The laboratory follows complementary strategies, including omics technologies (mainly next-generation sequencing and array-based profiling), functional experiments and bioinformatics approaches to identify diagnostic, prognostic and therapy-related biomarkers.
- Neurorehabilitation studies: we have evaluated a) the efficacy of different aspects of intensive multidisciplinary rehabilitation projects; b) the predictors of disability improvement; c) the effects of different symptomatic drugs.
- Development of innovative technologies: we evaluated the advantages obtained by GPS, an objective measurement of walking distance of pwMS, to better define their disability. Our MS Centre is the leading Centre in the RADAR project, which aims to improve patients’ quality of life and, potentially, to change the way to follow pts using wearable devices and remote monitoring technologies.
- Neuropsychological studies: we are carrying out studies to evaluate a) the emotional and cognitive aspects of pwMS during the early phase of the disease; b) the psychological correlations and the coping strategies developed after the disease onset, b) the risk perception and propensity in pwMS and MS Neurologists, and their influence on treatment choices.
We are also involved in studies on Neuromyelitis Optica and other rare CNS inflammatory diseases with a particular interest in their different clinical, epidemiological and therapeutical aspects.
Martinelli V, Dalla Costa G, Messina MJ et al. Multiple biomarkers improve the prediction of multiple sclerosis in clinically isolated syndromes. Acta Neurol Scand. 2017 Nov;136(5):454-461.
Cosorich I, Dalla Costa G, Sorini C, Ferrarese R, Messina MJ, Dolpady J, Radice E, Mariani A, Testoni PA, Canducci F, Comi G, Falcone M, Martinelli V. High frequency of intestinal T(H)17 cells correlates with microbiota alterations and disease activity in multiple sclerosis. Sci Adv. 2017 Jul 12;3(7):e170049.
Zecca C, Merlini A, Disanto G, Rodegher M, Panicari L, Romeo MA, Candrian U, Messina MJ, Pravatà E, Moiola L, Stefanin C, Ghezzi A, Perrone P, Patti F, Comi G, Gobbi C, Martinelli V. Half-dose fingolimod for treating relapsing-remitting multiple sclerosis: Observational study. Mult Scler. 2017 Feb 1:1352458517694089.
Radaelli M, Moiola L, Sangalli F et al. Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients. Mult Scler. 2016 Apr;22(4):511-9.
Esposito F, Sorosina M, Ottoboni L et al. A pharmacogenetic study implicates SLC9a9 in multiple sclerosis disease activity. Ann Neurol. 2015 Jul;78(1):115-2.
Romeo M, Martinelli V, Rodegher M et al. Validation of 1-year predictive score of long-term response to interferon-β in everyday clinical practice multiple sclerosis patients. Eur J Neurol. 2015 Jun;22(6):973-80.
Martinelli V, Dalla Costa G, Colombo B, et al. Vitamin D levels and risk of multiple sclerosis in patients with clinically isolated syndromes. Multiple Sclerosis 2014 Feb;20(2):147-55.
Martinelli V, Cocco E, Capra R et al. Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. Neurology 2011 Nov 22;77(21):1887-95.
Comi G., Martinelli V, Rodegher M. et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009 Oct 31;374(9700):1503-11.
Martinelli V, Rocca M A, Annovazzi P et al. A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS. Neurology 2009 Dec 1;73(22):1842-8.